| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bortezomib (often abbreviated as BTZ) is a proteasome inhibitor that has been approved for the treatment of certain types of cancers, most notably multiple myeloma and mantle cell lymphoma. Mechanism of Action Proteasome Inhibition: Bortezomib targets the 26S proteasome, a complex responsible for degrading ubiquitinated proteins. By inhibiting the proteasome’s activity, bortezomib causes an accumulation of unwanted or misfolded proteins within the cell. Induction of Apoptosis: The buildup of these proteins leads to cellular stress and activation of the unfolded protein response (UPR). In cancer cells, which often have high levels of protein synthesis and turnover, this stress quickly tips the balance toward apoptosis (programmed cell death). Disruption of Cell Signaling Pathways: Proteasome inhibition affects several signaling pathways, including the nuclear factor-kappa B (NF-κB) pathway. NF-κB is a key regulator of cell survival, proliferation, and inflammation. Its inhibition contributes to decreased survival signals for cancer cells, enhancing the cytotoxic effects of the treatment. Bortezomib — Bortezomib is a dipeptidyl boronic acid small-molecule antineoplastic that functions as a reversible proteasome inhibitor, with highest functional relevance at the chymotrypsin-like catalytic activity of the 26S proteasome. It is a conventional cytotoxic/targeted hematologic oncology drug, marketed most prominently as Velcade, and commonly abbreviated BTZ. Clinically, it is an established systemic therapy for multiple myeloma and mantle cell lymphoma, with administration by subcutaneous or intravenous route rather than oral delivery. Its therapeutic niche is strongest in proteostasis-dependent malignancies, especially plasma-cell disorders, where high secretory load and unfolded-protein stress make malignant cells particularly vulnerable to proteasome blockade. Primary mechanisms (ranked):
Bioavailability / PK relevance: Bortezomib is not used orally in standard oncology practice because systemic delivery is by SC or IV administration. SC exposure is clinically comparable to IV for efficacy-relevant proteasome inhibition, with lower neuropathy risk. It is widely distributed, undergoes hepatic oxidative metabolism, and shows a long apparent terminal half-life after repeated dosing; hepatic impairment is more PK-relevant than renal impairment for dose adjustment. In-vitro vs systemic exposure relevance: Many mechanistic cell-culture studies use low-nanomolar to higher-nanomolar or submicromolar concentrations; the clinically relevant range is plausible for direct proteasome inhibition, but some exaggerated ROS, mitochondrial, or combination effects in vitro may require longer exposure or higher concentrations than are uniformly sustained in patients. Because bortezomib is target-engaged at the proteasome rather than simply concentration-driven bulk exposure, pharmacodynamic proteasome inhibition is more informative than plasma concentration alone. Clinical evidence status: Approved standard-of-care systemic anticancer drug with robust human evidence, including randomized phase III data and long-standing regulatory approval in multiple myeloma and mantle cell lymphoma. Evidence is strongest in hematologic malignancy regimens and weaker/inconsistent for solid tumors as single-agent therapy. Mechanistic profile
P: 0–30 min |
| Source: |
| Type: |
| Cellular stress response related to the endoplasmic reticulum (ER) stress, which involves protein folding, quality control, and signaling pathways. The unfolded protein response (UPR) is the cells' way of maintaining the balance of protein folding in the endoplasmic reticulum. (UPR) is triggered by the presence of misfolded proteins in the endoplasmic reticulum. The UPR is a cellular stress response activated by the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER). - It is primarily mediated by three ER-resident sensors: IRE1α, PERK, and ATF6. Cancer cells often experience high levels of protein synthesis, hypoxia, nutrient deprivation, and oxidative stress, all of which can activate the UPR. – Numerous studies have reported that key UPR components (e.g., GRP78/BiP, IRE1α, PERK, CHOP) are overexpressed in various malignancies such as breast, pancreatic, lung, and prostate cancers. Unfolded Protein Response is typically upregulated in cancers and is associated with poorer prognosis due to its role in promoting cell survival, adaptation to stress, and therapeutic resistance. Although the UPR harbors the potential for tumor-suppressive (apoptotic) effects under severe stress conditions, its predominant activation in tumors supports an adaptive, protumorigenic state that facilitates cancer progression. Targeting UPR components and modulating this balance remain promising therapeutic strategies. |
| 5674- | BTZ, | Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects |
| - | in-vivo, | GBM, | NA | - | in-vivo, | HNSCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:257 Target#:459 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid